Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia

详细信息    查看全文

• 作者：Á ; ngel L. Montejo^a ; ^{amontejo@usal.es" class="auth_mail" title="E-mail the corresponding author} ; Celso Arango^b ; Miguel Bernardo^c ; José ; L. Carrasco^d ; Benedicto Crespo-Facorro^e ; Juan J. Cruz^f ; Javier del Pino^g ; Miguel A. Garcí ; a Escudero^h ; Clemente Garcí ; a Rizo^c ; Ana Gonzá ; lez-Pintoⁱ ; Ana I. Herná ; ndez^j ; Manuel Martí ; n Carrasco^k ; ^l ; Fermin Mayoral Cleries^m ; Jaqueline Mayoral van Sonⁿ ; M. Teresa Mories^o ; Isabella Pachiarotti^p ; Salvador Ros^q ; Eduard Vieta^p
• 刊名：Revista de Psiquiatría y Salud Mental (English Edition)
• 出版年：2016
• 出版时间：July-September 2016
• 年：2016
• 卷：9
• 期：3
• 页码：158-173
• 全文大小：1773 K

文摘

Iatrogenic hyperprolactinaemia (IHPRL) has been more frequently related to some antipsychotic drugs that provoke an intense blockade of dopamine D2 receptors. There is a wide variation in clinical practice, and perhaps some more awareness between clinicians is needed. Due to the high frequency of chronic treatment in severe mental patients, careful attention is recommended on the physical risk. IHPRL symptoms could be underestimated without routine examination.

Methodology

An intense scientific literature search was performed in order to draw up a multidisciplinary consensus, including different specialists of psychiatry, endocrinology, oncology and internal medicine, and looking for a consensus about clinical risk and detection of IHPRL following evidence-based medicine criteria levels (EBM I–IV).

Results

Short-term symptoms include amenorrhea, galactorrhoea, and sexual dysfunction with decrease of libido and erectile difficulties related to hypogonadism. Medium and long-term symptoms related to oestrogens are observed, including a decrease bone mass density, hypogonadism, early menopause, some types of cancer risk increase (breast and endometrial), cardiovascular risk increase, immune system disorders, lipids, and cognitive dysfunction. Prolactin level, gonadal hormones and vitamin D should be checked in all patients receiving antipsychotics at baseline although early symptoms (amenorrhea–galactorrhoea) may not be observed due to the risk of underestimating other delayed symptoms that may appear in the medium term. Routine examination of sexual dysfunction is recommended due to possible poor patient tolerance and low compliance. Special care is required in children and adolescents, as well as patients with PRL levels >50 ng/ml (moderate hyperprolactinaemia). A possible prolactinoma should be investigated in patients with PRL levels >150 ng/ml, with special attention to patients with breast/endometrial cancer history. Densitometry should be prescribed for males >50 years old, amenorrhea >6 months, or early menopause to avoid fracture risk.